Aimee M. Crago, MD, PhD
Surgeon
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Soft Tissue Sarcoma
- Gastrointestinal Stromal Tumor
- Malignant Fibrous Histiocytoma
Request an Appointment
About Me
- Associate Attending Surgeon
I am a surgical oncologist at Memorial Sloan Kettering who specializes specifically in caring for people with soft tissue sarcoma. Sarcoma is a rare cancer with more than 80 subtypes, each with its own treatment strategy. I understand the challenges each subtype poses. I use my expertise to provide my patients with an individualized recommendation about the best treatment for them.
Read more
Along with members of the pathology, radiation oncology, and medical oncology departments, I design treatment plans that optimize my patients’ chance for a cure. As much as possible, each patient should be able to return to normal after surgery. I almost always perform limb-sparing procedures for tumors on the legs and arms. When it is safe to do so, I use laparoscopic and minimally invasive techniques for tumors in and around the abdomen.
After surgery, I follow my patients long-term to help them deal with any side effects. I closely monitor patients who are at an increased risk of developing a second sarcoma, such as those with Gardner’s syndrome or neurofibromatosis. If we detect those tumors early, we can reduce the long-term complications.
In addition to seeing patients, I conduct an active research program. I look at the genetic errors that lead to the development of soft tissue tumors, such as liposarcomas, solitary fibrous tumors, and desmoid-type fibromatosis. These changes can be used to identify new drugs to treat the tumors. The research can also help us predict which patients may benefit most from specific treatments. My work has been funded by a range of organizations, including the American Cancer Society, the Food and Drug Administration, the American Society of Clinical Oncology, the American College of Surgeons, and the Kristen Ann Carr Foundation.
I am actively involved in teaching other doctors about caring for people with sarcoma. I also write articles, book chapters, and reviews on the management and biology of soft tissue sarcomas, and serve on multiple editorial boards. I am on the board of the Melanoma and Sarcoma Disease Site Working Group for the Society of Surgical Oncology and I chair the Scientific Advisory Board of the Desmoid Tumor Research Foundation. My leadership roles and research allow me to continuously improve treatment, not only for my own patients and those of our team but also for soft tissue sarcoma patients around the world.
A surgeon is a doctor with special training in many kinds of surgery.
My Specialties
- Soft Tissue Sarcoma
- Gastrointestinal Stromal Tumor
- Malignant Fibrous Histiocytoma
- Desmoid Tumor
- Solitary Fibrous Tumor
- Malignant Peripheral Nerve Sheath Tumor
- Neurofibromatosis
- Gardner’s Syndrome
Education
- MD, Harvard University
Residencies
- General Surgery - Georgetown University Medical Center
Fellowships
- Surgical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Surgery
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Crago sees patients at three locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Selected Book Chapters
Crago AM and Singer S. Soft Tissue Sarcoma. ACS: Principles and Practice of Surgery Ontario: Decker; 2011.
Singer, S, Tap, WD, Crago, AM, and O’Sullivan, B. Soft Tissue Sarcoma. VT DeVita, TS Lawrence, SA Rosenberg. Cancer: Principles & Practice of Oncology Wolters Kluwer Health; 2014; 10th.
Crago AM. Soft Tissue Sarcoma – Extremity. in Clinical Decision Support: Surgery, edited by Lillemoe K, de Moya M, House M, Hutter M. 2016. Decision Support in Medicine, LLC. Wilmington, DE.
Crago AM and Singer S. Soft Tissue Sarcoma. Scientific American Surgery Ontario: Decker; 2015.
Gounder, M, Ravi, V, Yamada, Y, Carvajal, R, and Crago, A. Sarcoma of Soft Tissue. American Cancer Society Textbook of Clinical Oncology, in press.
Visit PubMed for a full listing of Dr. Crago’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Aimee M. Crago discloses the following relationships and financial interests:
-
Springworks Therapeutics
Professional Services and Activities (Uncompensated)
-
Wolters Kluwer
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].